From therapies that replace disease-causing genes with normal ones to CRISPR-based treatments that edit genes inside the body, the biotech industry has made tremendous strides in genomic medicine. Despite these advances, today’s approaches still have requirements that limit their accessibility. Ensoma hopes to change that with a suite of off-the-shelf genomic medicines.

Hyperfine Research has raised $90 million to scale up the commercial rollout of its wheeled, bedside MRI scanner in the U.S. and abroad, following its debut last year.

AstraZeneca has dropped two oncology programs from its clinical-phase pipeline. The Big Pharma has stopped work on AZD9496 in breast cancer and imaradenant in prostate cancer on safety or efficacy grounds.

Just over a year after Illumina’s $1.2 billion bid for its fellow sequencer manufacturer fell apart under federal scrutiny, Pacific Biosciences has secured a new benefactor with a $900 million commitment from SoftBank.

Monoclonal antibodies have transformed the treatment of many diseases from cancer to autoimmune disorders. But the approach has its limitations, prompting scientists and companies to develop the next generation of antibody treatments and other biologics.

Several companies are working to make cell therapies cheaper and more widely available by making them from donor cells rather than patients’ own cells. Notch Therapeutics is going one step further with cancer treatments based on stem cells rather than mature T cells, and it’s raised $85 million to back that mission.

Gilead has sunk billions into Galapagos over the past few years, but this is quickly turning into one of the most disastrous biotech deals in recent history.

It’s been a busy year for Day One Biopharmaceuticals. Just nine months after debuting with $60 million to tackle childhood cancers, the company is topping up its coffers with a $130 million series B financing. The funds will bankroll development and launch plans for its lead program, a pan-RAF inhibitor it’s developing for children with brain cancer, as well as its search for new drug programs to pick up.

Toronto, Ontario – Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company”), a developer of MedTech innovation, is pleased to announce that it has committed to participate in the RTO financing of Glow LifeTech (“Glow”), a privately held Canadian-based biotechnology company in which Relay currently holds a significant equity interest.

Drug Farm has raised $56 million to take its lead hepatitis B treatment into the clinic. The series A round will equip Drug Farm to start learning whether its mutagenesis-based approach to drug target discovery translates into effective therapies.